Current Trends in the Management of Homozygous ß-Thalassemia
|
|
- Oscar Thompson
- 5 years ago
- Views:
Transcription
1 Review Article Current Trends in the Management of Homozygous ß-Thalassemia From the Yale University School of Medicine, New Haven. Howard A. Pearson, MD Address reprint requests and correspondence to Dr. Pearson: Yale University School of Medicine, Department of Pediatrics, 333 Cedar Street, New Haven, CT 66510, USA. Accepted for publication 2 March Received 6 February HA. Pearson, Current Trends in the Management of Homozygous ß-Thalassemia. 1996; 16(5): ß-thalassemia is a genetic disease associated with decreased production of the ß-polypeptide chains of human hemoglobin. More than 100 different mutations have been identified that produce the thalassemia phenotype. Persons with the heterozygous state, thalassemia trait, have a mild microcytic anemia, with hemoglobin levels 1 to 2 g/dl below appropriate age and gender normal levels. Individuals with thalassemia trait usually have no symptoms. In contrast, homozygosity for thalassemia genes usually results in thalassemia major (TM) or Cooley's anemia, a severe, transfusion-dependent hemolytic anemia. The management of TM has undergone significant changes over the last two decades. This review will outline the management of these patients, the therapeutic considerations currently available and possible future interventions. The lifelong management of patients with TM involves several decision points and considerations: 1) The criteria for initiating transfusions. 2) The transfusion regimen: the blood product to be used, frequency of transfusions, and desired levels of hemoglobin to be maintained. 3) The criteria for performing splenectomy and the management of postsplenectomy complications. 4) The criteria for initiating chelation therapy with deferoxamine (DF) and the regimen to be used. 5) The periodic evaluation of DF therapy. 6) Results of modern transfusion and chelation therapy. 7) The status of oral iron chelating agents. 8) Prenatal diagnosis. 9) Bone marrow transplantation. 10) Pharmacological treatment. 11) The prospects for gene therapy. Criteria for Transfusions Almost all patients with TM require blood transfusion within the first two to three years of life to prevent severe anemia and its physical consequences. TM patients who are not transfused will only survive for a few years, although there is some variability in the age at which transfusions become necessary. 1 More than 70% of patients require transfusions by two years of age, and more than 90% require transfusions by five years of age. However, 5% to 10% of patients, who are usually designated as having "thalassemia intermedia" (TI), are able to maintain reasonable levels of hemoglobin (>70 g/l) without regular transfusions. Such TI patients usually have genetic mutations that result in less severe hematological disease. 2 A diagnosis of TM is made on the basis of a severe erythroblastic hemolytic anemia, typical RBC morphology, greatly elevated levels of Hb F, splenomegaly and marked expansion of the erythroid marrow that produces characteristic roentgenographic changes of the long bones and skull. 3 Both parents usually have ß-thalassemia trait, a mild hypochromic, microcytic anemia (MCV <78 f1) with elevated levels of Hb A 2 (>3.5%). An occasional microcytic parent will have normal levels of Hb A 2, but levels of Hb F >5.0% the so-called ß-δ thalassemia trait. Other parents may have a minor (5% to 10%) hemoglobin in the Hb S electrophoretic position called the Lepore hemoglobin. These trait variants are similar to the high A 2 thalassemia trait. 4 The newly diagnosed infant should be followed regularly. If the hemoglobin level falls consistently below 60 to 70 g/l, transfusions should be initiated. Even at these relatively high levels, if the child develops symptoms such as tachypnea, tachycardia, weakness, increased sleeping and growth failure, transfusions should also be begun. Some patients with TI may not require transfusions on the basis of their hemoglobin levels alone, but are begun on transfusions because of symptoms or because of progressive cosmetic changes of the face or bony changes resulting in pathologic fractures. The Transfusion Regimen Before transfusions are begun, RBC genotyping, which is as extensive as possible, should be done. After a child
2 begins receiving regular transfusions, it may be difficult to ascertain the RBC genotype. A small proportion of TM patients develop severe isoimmunization against multiple blood groups and even autoimmunization, which may make further transfusions difficult or even impossible. 5 If it has not been done previously, the patient should receive hepatitis B immunization. Transfusions should use packed or concentrated RBCs from which WBCs have been removed as completely as possible. This can be accomplished by using specific WBC filters, by washing the RBCs with large amounts of saline and centrifugation, or by the use of deglycerolized frozen RBCs. Removal of WBCs prevents the development of WBC antibodies and avoids febrile reactions, making transfusion premedication with antihistamines and hydrocortisone unnecessary. It is important to know the hematocrit of the RBC preparation that will be used. This information is necessary to determine the dose of RBCs to be administered with each transfusion and to estimate the survival of the transfused RBCs. The dose of RBCs to be given with each transfusion is based upon the hematocrit (HCT) of the RBC preparation, the frequency of transfusions and the child's weight. In general, a dose of 15 ml/kg of RBCs that have an HCT of 65% to 70% will raise the hemoglobin about 50 g/l. It is necessary to give approximately 20 ml/kg for the same increase if the RBCs have an HCT of 50% to 55%. These amounts of RBCs should require transfusion every four to five weeks to maintain a desired hemoglobin level. There are two philosophies concerning the lowest level of hemoglobin that should be maintained. The "hypertransfusion" regime attempts to keep the hemoglobin above 95 to 100 g/l. 6 The "supertransfusion" regimen attempts to keep the hemoglobin level above 120 g/l. 7 Because the supertransfusion regimen may require more frequent transfusions (every two to three weeks), most American centers are now employing "hypertransfusion." The hypothetical advantages of "supertransfusion," such as complete shut-off of erythropoiesis, greater reduction of GI iron absorption, and decreased blood volume, do not appear to have sufficient long-term benefits to balance the inconvenience and expense of more frequent transfusions. A number of studies have been done utilizing "neocyte" transfusions. Neocytes are prepared by centrifugation of blood to concentrate the younger, less dense RBCs. 8 Administration of young red cells with increased survival (neocytes) should theoretically reduce transfusion requirements. However, most studies have shown only a modest reduction which did not justify the increased expense and exposure to increased numbers of donors. 9 The Criteria for Splenectomy Most patients with homozygous ß-thalassemia require splenectomy at some time in their lives. In the past, before the use of hypertransfusion, the spleen often became massively enlarged in early infancy, and splenectomy was necessary to relieve the mechanical burden caused by its very large size. When splenectomy was done before six years of age, there was a high risk (10% to 20%) of severe postsplenectomy sepsis infection (PSI), which had a high rate of morbidity and mortality. 10 With the use of hypertransfusion, massive splenomegaly is unusual. Today the usual indication for splenectomy is evidence of increased destruction of transfused RBCs, which is indicated by an increased transfusion requirement. For example, a patient who has maintained a desired hemoglobin level (>100 g/l) with transfusions of 15 ml/kg of packed RBCs every four weeks is noted to require transfusions every two to three weeks to maintain this level. Annual transfusion requirements (ml of RBCs/kg/year) give an indication of RBC survival. If the RBCs have a normal survival, the annual blood utilization should be 175 to 200 ml RBCs/kg/year. Amounts in excess of 200 ml/kg/year indicate hypersplenism and are a reason to consider splenectomy. In almost every instance, it is possible to defer splenectomy until after six years of age, when the risk of PSI decreases greatly. 11 Following splenectomy, transfusion requirements are reduced considerably. Prior to elective splenectomy, immunization with pneumococcal and H. influenzae polysaccharide vaccines should be given. These patients regularly develop thrombocytosis after splenectomy. Thrombotic episodes have not been reported, even with platelet counts 1,000,000/mm 3 or even greater. Some centers advocate the use of low-dose salicylate therapy postsplenectomy, but there are no studies indicating that this is necessary. Because patients with asplenia have an increased risk of severe bacterial infections (PSI), prophylactic antibiotics are often advocated. Prophylactic penicillin (penicillin V, 125 mg to 250 mg p.o., b.i.d.) should always be given to children under five years of age. Prophylactic antibiotics in children over five years of age are probably not necessary. A study of children with the splenic dysfunction of sickle cell anemia showed a very low incidence of severe infection in children over five years of age and no significant difference between the incidence of severe infection in children receiving either penicillin or placebo. 12 However, asplenic patients and their families must understand that significant fever (>38.8 degrees C) may indicate a severe infection regardless of their age and whether prophylactic antibiotics are being used. Febrile, asplenic children must be examined immediately by a physician. A blood culture should be obtained and intravenous injection of a therapeutic dose of a broad spectrum
3 antibiotic should be given. The potential seriousness of fever in asplenic children must be reemphasized regularly. There are other unusual infections that occur in TM patients. A number of reports have described severe enterocolitis, caused by Yersinia enterocolitica, in TM patients. 13 Meningitis caused by Vibrio vulnificus has also been reported. 14 It is not clear whether these and other unusual infections occur because of asplenia or because of iron overload and the use of deferoxamine (DF). Criteria and Regimen for Chelation Therapy Patients receiving regular RBC transfusions inevitably develop iron overload. Transfusion of 200 ml of packed RBCs ultimately results in deposition of about 200 mg of iron into the tissues. Because there is no physiologic mechanism for iron excretion, repeated transfusions cause hemosiderosis, a pathologic accumulation of iron, especially in the liver, the endocrine organs and the heart. This results in organ dysfunction such as diabetes mellitus, congestive heart failure and cardiac arrhythmias. The average life expectancy of thalassemia patients is less than 20 years and survival beyond 30 years is unusual unless progressive hemosiderosis can be prevented. This unfavorable prognosis has been improved by iron chelation therapy, the administration of iron-chelating agents that combine with body iron and facilitate excretion in the urine and stool. The only iron-chelator currently available is deferoxamine (Desferal, DF). DF is an effecting chelating agent that is nearly specific for iron. Unfortunately, DF is not effective when given orally and so it must be administered parenterally, either subcutaneously (s.c.) or intravenously. Parenteral DF is rapidly cleared from the body and so must be injected repeatedly or administered over an extended period of time. Current DF protocols involve 10- to 12-hour s.c. or IV continuous injections of DF using small battery-driven infusion pumps. The subcutaneous route is generally used. The dose of DF is 30 to 40 mg/kg/day, diluted in 8 to 15 ml of distilled water. Patients are encouraged to use the DF pump five to six nights per week during sleep. DF-induced urinary iron excretion can be enhanced by the administration of 100 mg of ascorbic acid given on the days DF is used. Larger doses of ascorbic acid may produce iron toxicity in overloaded patients and should not be given. DF is remarkably safe. Auditory, visual and bony abnormalities have been described, but these have only occurred with DF doses in excess of 60 mg/kg/day. True allergy to DF has been rare, although many patients develop hard, painful lumps at the site of subcutaneous injections. These are probably due to needle position rather than allergy, because they do not occur every time DF is used and they cannot be prevented by the addition of hydrocortisone to the DF solution. Development of these painful lumps at subcutaneous injection sites is a frequent reason for poor compliance. DF is effective when administered intravenously, and use of permanent implanted intravenous catheters (Portocath) have been employed successfully. The major problem with DF therapy is patient noncompliance with the difficult, expensive and sometimes painful regimen, which must be given repetitively for an indefinite period of time. Compliance may also decrease because there is no immediate "positive feedback;" the patient notices no immediate symptoms when the medication is not used, even for long periods of time. The time to begin DF chelation therapy varies. DF is not effective until a significant excess of iron is present in the tissues. Further, DF toxicity is increased in patients who are not iron-overloaded to some degree. One accepted indication is to begin chelation therapy when the serum ferritin level is >1500 μg/l. Another indication is when the child has been on "hypertransfusion" for four to five years. A final indication utilizes a test dose of intramuscular DF with measurement of urinary iron excretion. 16 At the present time, there is no effective, safe oral iron chelating agent available. Studies with 1-2 dimethyl hydroxypyrid (L-1), an oral iron chelating agent, are currently being conducted in Europe and Canada. The drug is administered orally three to four times a day. L-l is not as effective as DF, and toxicity, especially by neutropenia, has been observed in a significant number of patients. 17 Evaluation of DF Chelation Therapy The child receiving DF therapy should be evaluated periodically. Height, weight, and Tanner staging should be measured. Bone age should be determined. Cardiac function should be assessed by echocardiography, including left ventricular ejection fraction. A 24-hour Holter monitor should be performed. Laboratory studies include serum ferritin, liver function tests, thyroid assessment, oral glucose tolerance test, and serum electrolytes, including Ca and PO 4. These tests can be modified or expanded, depending upon the patient's age. Results of Modern Transfusion and Chelation Therapy Morbidity and mortality of thalassemia major has been significantly improved by modern therapy. The severe
4 skeletal changes and the cosmetic abnormalities characteristic of thalassemia major in the past can be prevented. When chelation therapy is begun in early childhood and continued regularly, the complications of hemosiderosis can be prevented. There has been significant increase in life expectancy in children treated by these modern techniques. 18,19 In 1973, the average age of thalassemia patients in the US and Canada was 11 years. In 1993, the average age was 19 years. 20 Many patients are growing normally and undergoing age-appropriate puberty, events rarely seen 20 years ago. However, it must be noted that some patients who began chelation therapy after 10 years of age have not grown normally, have not had spontaneous puberty, and have evidence of hepatic, endocrine and cardiac damage. Because of a high rate of noncompliance with DF therapy, many patients continue to develop the complications of hemosiderosis. Prenatal Diagnosis Modern DNA technologies have precisely identified many specific thalassemia genes. This has permitted accurate prenatal diagnosis of thalassemia major. In at-risk pregnancies (both parents have thalassemia trait), prenatal diagnosis can be performed in the first trimester of pregnancy, using fetal DNA obtained by chorionic biopsy. The fetal genotype, homozygous or heterozygous thalassemia or normal, can be established, giving the parents the option of terminating severely affected pregnancies. Extensive carrier testing, combined with prenatal diagnosis, has been very successful in reducing the numbers of thalassemia major births in Greece, Italy and in the United States Bone Marrow Transplantation BMT offers the only cure available for thalassemia major. This has been extensively performed by Professor Lucarelli in Italy, who has done BMT in more than 400 patients with thalassemia major. 24 BMT has been performed much less frequently elsewhere in the world. In the US, only 32 BMTs for TM were reported through early Lucarelli's results indicate a 70% to 80% cure when good-risk thalassemia patients (young patients who do not have significant hepatic fibrosis) have an HLA- and MLC-compatible bone marrow transplant from a normal or thalassemia trait sibling. Some physicians and families, however, are unwilling to accept an immediate risk of death, which may be as high as 10% to 15%, as well as the possibility of graft rejection or graft-versus-host disease. There is little doubt that successful BMT is cost effective. The high, one-time cost of BMT is considerably less than the costs of chronic transfusions and DF chelation therapy. In parts of the world where availability of blood and DF is limited, BMT may be the treatment of choice if there is a histocompatible donor. BMT might also be indicated in patients who are chronically noncompliant with DF therapy. Pharmacological Therapy of Thalassemia Infants with homozygous TM are not anemic at birth, because they efficiently produce large amounts of fetal hemoglobin which contains γ, as opposed to ß, polypeptide chains. After birth, γ chains are produced in very small quantities because of the so-called γ-ß switch mechanism. The deficiency of γ chains and the lack of production of ß chains caused by homozygous thalassemia mutations result in a marked excess of α chains. Excess α chains precipitate in the RBCs, causing membrane damage and premature RBC destruction in the bone marrow (ineffective erythropoiesis). If it were possible to stimulate more effective γ-chain synthesis in later life, some of the abnormal pathophysiology of thalassemia major could be improved. A number of chemical agents can increase fetal hemoglobin synthesis in experimental animal studies, and a few of these have been studied in patients, including patients with TM and TI. These drugs include erythropoietin, cancer chemotherapeutic agents (hydroxyurea, HU, and 5-Aza cytidine), and most recently, derivatives of butyric acid. 26 The responses to these drugs in TM have been inconstant and, in general, disappointing. Short-term, continuous parenteral infusions of butyric acid derivatives have produced increases in hemoglobin levels in small numbers of patients. 27 However, the responses were not sustained. 28 The best results have been obtained in a few (four of 11) patients with TI who were treated with large doses of oral sodium phenylbutyrate. These patients showed increases of hemoglobin of 2 to 4 g/dl, which have been sustained for more than two years. 29 Studies are currently underway using combinations of these various drugs, but they currently appear to have limited clinical value. Gene Therapy The replacement of the abnormal thalassemia ß gene in RBC precursors with a normal ß gene could cure TM. Hemoglobinopathy gene therapy would require not only large amounts of ß-globin chain synthesis, but also complex
5 regulation of the balance between α and ß-chain production. An alternative strategy for gene therapy could involve the reactivation of γ chain synthesis by reversing the so-called γ-ß switch. However, gene therapy for TM appears to be in the distant future. Diseases whose control would require production of only small amounts of gene product, such as adenine deaminase-related immunodeficiency, are the current focus of most gene replacement research in humans. References 1. Silvestroni E, Bianco I. Screening for microcytosis in Italy. Am J Hum Gen 1975;27: Pearson HA. Thalassemia intermedia. Ann NY Acad Sci 1964;119: Caffey J. Cooley's anemia: a review of the roentgenographic findings. Am J Rad 1957;78: Pearson HA. Clinical aspects of the ß-thalassemias. In: Handin RI, Lux SE, Stossel TP, editors. Blood, Principles and Practice of Hematology. Philadelphia: Lippincott, 1995: Kruatrachue M, Sirisinha S, Pacharee P, et al. An association between thalassemia and autoimmune hemolytic anemia. Scand J Haematol 1980;25: Piomelli S, Karpatkin M, Arzanian M, et al. Hypertransfusion regimen in patients with Cooley's anemia. Ann NY Acad Sci 1974;232: Propper RD, Button LN, Nathan DG. New approaches to the transfusion management of thalassemia. Blood 1980;55: Corash L, Klein H, Deisseroth A, et al. Selective isolation of young erythrocytes for transfusion support of thalassemia major patients. Blood 1981;57: Cohen AR, Schmidt JM, Martin MB, et al. Clinical trial of young red cell transfusions. J Pediatr 1984;104: Smith CH, Erlandson ME, Stern G, et al. Postsplenectomy infection in Cooley's anemia. N Engl J Med 1962;266: Singer DB. Postsplenectomy sepsis. Perspect Ped Path 1973; 1: Falletta J, Wools GM, Veiter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 1995;127: Roche G, Leheup B, Gerard A, et al. Septicemia: a Yersinia enterolitica revue generate. Rev Med Intern 1982;3: Katz BZ. Vibrio vulnificus meningitis in a boy with thalassemia after eating raw oysters. Pediatrics 1988;82: Propper ED, Cooper B, Ruffo RR, et al. Continuous subcutaneous administration of desferrioxamine in patients with iron overload. N Engl J Med 1977;297: Smith RS. Iron excretion in thalassemia major after administration of chelating agents. Br Med J 1962;1: Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79: Giardina PJ, Grady RW, Ehlers JM, et al. Chelation therapy in Cooley's anemia: a decade of experience with subcutaneous desferrioxamine in thalassemia major. Ann NY Acad Sci 1990;612: Olivieri NG, Nathan DG, MacMillan JH, et al. Survival of medically treated patients with homozygous ß-thalassemia. N Engl J Med 1994;331: Pearson HA, Cohen AR, Giardina PJ, et al. Survival and demography in thalassemia major. Pediatrics Alter BP. Antenatal diagnosis of thalassemia. Ann NY Acad Sci 1985;445: Cao A, Rossatelli C, Gallenello R, et al. The prevention of homozygous beta thalassemia by carrier screening and prenatal diagnosis in Sardinia. Clin Genet 1989;36: Pearson HA, Guiliotis DK, Rink L, et al. Patient age distribution in thalassemia major: changes between 1973 and Pediatrics 1987;80: Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in thalassemia. N Engl J Med 1990;322: Walters MC, Thomas ED. Bone marrow transplantation for thalassemia. The USA experience. Am J Ped Hem Onc 1994;16: Stamatoyannopoulos GA, Nienhuis AW. Therapeutic approaches to hemoglobin switching in treatment of the hemoglobinopathies. Ann Rev Med 1992;43:497.
6 27. Perrine SP, Gonder GD, Little J, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the ß globin disorders. N Engl J Med 1993:338: Sher GD, Gonder GD, Little J, et al. Extended therapy with intravenous arginine butyrate in patients with ß- hemoglobinopathies. N Engl J Med 1995,332: Dover DJ, Brusolow SW, Samid DV. Increased fetal hemoglobin in patients receiving sodium 4 phenylbutyrate. N Engl J Med 1995:337.
The Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola
7. The Nucleated Red The Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola Introduction The purpose of this study was to evaluate the performance of the
More informationIn adults, the predominant Hb (HbA) molecule has four chains: two α and two β chains. In thalassemias, the synthesis of either the α or the β chains
Thalassaemias Thalassemia Thalassemia is an inherited autosomal recessive blood disease. Associated with absence or reduction in a or b globin chains. Reduced synthesis of one of the globin chains can
More informationA group of inherited disorders characterized by reduced or absent amounts of hemoglobin, the oxygencarrying protein inside the red blood cells.
Thalassemia A group of inherited disorders characterized by reduced or absent amounts of hemoglobin, the oxygencarrying protein inside the red blood cells. Types of Thallasemia 1) Thalassemia trait 2)
More informationTHALASSEMIA AND COMPREHENSIVE CARE
1 THALASSEMIA AND COMPREHENSIVE CARE Melanie Kirby MBBS, FRCP (C), Hospital for Sick Children, Toronto Associate Professor of Paediatrics, University of Toronto. Objectives 2 By the end of this presentation,
More informationß-Thalassemia Major: Experience at King Fahad Hofuf Hospital, Al-Hassa, Saudi Arabia
Case Reports Adewale Ayodele Laditan, FRCP; Mohamed Amin El-Agib, DCH; Saad Al-Naeem, ABDP; Michael Georgeos, CES; Sameera Khabour, DCH From the Departments of Pediatrics (Drs. Laditan, El-Agib, Al-Naeem,
More informationAn overview of Thalassaemias and Complications
An overview of Thalassaemias and Complications Haemoglobin Haemoglobin is the most abundant protein in blood, and exists as three main types in normal adults: HbA ( ) - 97% HbA 2 ( ) - 2.5% HbF ( ) - 0.5%
More informationFetal Anemia 02/13/13. Anjulika Chawla, M.D. Assistant Professor Division of Pediatric Hematology/Oncology
Fetal Anemia 02/13/13 Anjulika Chawla, M.D. Assistant Professor Division of Pediatric Hematology/Oncology Objectives Definition of anemia Diagnosis of fetal anemia Normal developmental hematopoiesis Etiology
More informationPart I. Pathophysiology and management of Thalassemia Intermedia. M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan
Pathophysiology and management of Thalassemia Intermedia M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan 4th European Symposium on Rare Anaemias 3rd Bulgarian Symposium on Thalassaemia
More informationSICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN
SICKLE CELL DISEASE Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN Objective: The student should be able: To identify the presentation, diagnosis,
More informationTransfusion support in Thalassaemia. Dr.A.keerti 1 st year PG DEPT. OF TRANSFUSION MEDICINE
Transfusion support in Thalassaemia Dr.A.keerti 1 st year PG DEPT. OF TRANSFUSION MEDICINE Structure of hemoglobin Types of hemoglobins Hemoglobin-Development Switching Thalassaemia- introduction Classification
More informationThe Thalassemias in Clinical Practice. Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland
The Thalassemias in Clinical Practice Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland Outline Thalassemia: definitions and pathophysiology Epidemiology
More informationAnemia s. Troy Lund MSMS PhD MD
Anemia s Troy Lund MSMS PhD MD lundx072@umn.edu Hemoglobinopathy/Anemia IOM take home points. 1. How do we identify the condtion? Smear, CBC Solubility Test (SCD) 2. How does it present clincally? 3. How
More informationHow to Write a Life Care Plan for a Child with Hemoglobinopathy
How to Write a Life Care Plan for a Child with Hemoglobinopathy Tamar Fleischer, BSN, MSN, CNLCP & Mona Yudkoff, RN, MPH, CRRN, CNLCP BalaCare Solutions March 2018 St. Peterburg, Florida What is Hemoglobinopathy?
More information2. Transfusion Support in Thalassemia
2. Transfusion Support in Thalassemia Principles To promptly identify the indications to start blood transfusion in thalassemia patients To understand the rate and frequency of transfusion in thalassemia
More information1) Anemias Dr. Anwar Sheikha
1) Anemias Dr. Anwar Sheikha DEFINITION: Anemia can be defined as a reduction in the concentration of hemoglobin below what is normal for age and sex of the patient. This reduction of hemoglobin is usually
More informationThalassemia Maria Luz Uy del Rosario, M.D.
Thalassemia Maria Luz Uy del Rosario, M.D. Philippine Society of Hematology and Blood Transfusion Philippine Society of Pediatric Oncology What is Thalassemia Hereditary Hemoglobin disorder Hemolytic anemia
More informationHemolytic anemias (2 of 2)
Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy Mutation in the β-globin
More informationYear 2003 Paper two: Questions supplied by Tricia
QUESTION 65 A 36-year-old man presents in a post-ictal state after an observed generalised seizure. Full blood investigation shows: haemoglobin 0 g/l [128-175] mean corpuscular volume (MCV) 106 fl [80-7]
More informationGenetics of Thalassemia
Genetics of Thalassemia Submitted by : Raya Samir Al- Hayaly Sura Zuhair Salih Saad Ghassan Al- Dulaimy Saad Farouq Kassir Sama Naal Salouha Zahraa Jasim Al- Aarajy Supervised by : Dr. Kawkab Adris Mahmod
More informationΧριστίνα Χρυσοχόου Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών
Ιωάννης Ανδρέου Χριστίνα Χρυσοχόου Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών Ιπποκράτειο Γ.Ν.Α Splenectomy at the age of 7yrs Episodes of persistent atrial fibrillation Hypothyroidism Osteoporosis Noncompliant
More informationHigh Hemoglobin F in a Saudi Child Presenting with Pancytopenia
Case Report imedpub Journals http://www.imedpub.com Journal of Pediatric Care ISSN 2471-805X DOI: 10.21767/2471-805X.100002 High Hemoglobin F in a Saudi Child Presenting with Pancytopenia Abstract Saudi
More informationMicrocytic Hypochromic Anemia An Approach to Diagnosis
Microcytic Hypochromic Anemia An Approach to Diagnosis Decreased hemoglobin synthesis gives rise to microcytic hypochromic anemias. Hypochromic anemias are characterized by normal cellular proliferation
More informationWhat is Thalassaemia?
What is Thalassaemia? Introduction The thalassaemias are a diverse group of genetic blood diseases characterized by absent or decreased production of normal hemoglobin, resulting in a microcytic anemia
More informationDr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW
Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW Objectives Gain awareness of haemoglobinopathy inheritance, pathophysiology
More informationPreface: Thalassemia Bernard G. Forget
Thalassemia Preface: Thalassemia Bernard G. Forget xiii Thalassemia: An Overview of 50 Years of Clinical Research 1005 Vijay G. Sankaran and David G. Nathan The thalassemias are attributable to the defective
More informationEvaluation of Cardiac Complications in Patients with Thalassemia Major Using Serum Ferritin Levels
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijssJuneI/2017/016 Evaluation of Cardiac Complications in Patients with Thalassemia Major Using Serum Ferritin Levels Farideh
More informationPediatrics. Pyruvate Kinase Deficiency (PKD) Symptoms and Treatment. Definition. Epidemiology of Pyruvate Kinase Deficiency.
Pediatrics Pyruvate Kinase Deficiency (PKD) Symptoms and Treatment See online here Pyruvate kinase deficiency is an inherited metabolic disorder characterized by a deficiency in the enzyme "pyruvate kinase"
More informationClinical Guidelines on the Use of Iron Chelation in Children Receiving Regular Blood Transfusions
Clinical Guidelines on the Use of Iron Chelation in Children Receiving Regular Blood Transfusions Version: 1 Date: 4 th May 2010 Authors: Responsible committee or Director: Review date: Target audience:
More informationHaemoglobinophaties EBMT 2011 Data Manager session
Haemoglobinophaties EBMT 2011 Data Manager session Presentation plan Biological characteristics Clinical characteristics Transplant resuts What is different From transplant in malignancies Between Thalassemia
More informationC. treatment with Desferal (deferoxamine mesylate USP, iron-chelating agent)
HEMOLYTIC ANEMIAS Single choice tests 1. Select the clinical manifestation that is not characteristic for the hemolytic crisis: A. decrease of the red blood cell count B. reticulocytosis C. jaundice D.
More informationEditorial PRESENT STATUS OF HEMOGLOBINOPATHIES IN INDIA
Editorial PRESENT STATUS OF HEMOGLOBINOPATHIES IN INDIA The last decade has witnessed an enormous progress in the field of hemoglobinopathies. This explosion in knowledge came in the wake of advances in
More informationIron Overload in Sickle Cell Disease Review of Cause and Treatment
Iron Overload in Sickle Cell Disease Review of Cause and Treatment Susan M. Carson RN, MSN, CPNP Nurse Practitioner III Hematology Program Children s Hospital Los Angeles Objectives Describe the effect
More informationHaemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD
Haemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD Introduction is the iron-containing oxygen transport metalloprotein in the red blood cells Hemoglobin in the blood carries oxygen from the respiratory organs
More informationHydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
More informationArticle Stem cell transplantation for thalassaemia
RBMOnline - Vol 10. No 1. 2005 111-115 Reproductive BioMedicine Online; www.rbmonline.com/article/1525 on web 10 November 2004 Article Stem cell transplantation for thalassaemia Dr Javid Gaziev Javid Gaziev
More informationRed cell disorder. Dr. Ahmed Hasan
Red cell disorder Dr. Ahmed Hasan Things to be learned in this lecture Definition and clinical feature of anemia. Classification of anemia. Know some details of microcytic anemia Question of the lecture:
More informationThalassaemia. What is thalassaemia? What causes thalassaemia? What are the different types of thalassaemia?
Thalassaemia Thalassaemia is an inherited condition affecting the blood. There are different types, which vary from a mild condition with no symptoms, to a serious or lifethreatening condition. For the
More informationProf Sanath P Lamabadusuriya
Prof Sanath P Lamabadusuriya What is Thalassaemia? It is the commonest inherited variety of anaemia It is the commonest haemoglobinopathy in Sri Lanka Of all the different types, Beta-Thalassaemia major
More informationHypochromic Anaemias
Hypochromic Anaemias Dr Mere Kende MBBS, MMED (Path), MAACB, MACTM, MACRRM LECTURER-SMHS Anaemia LOW HEMOGLOBIN Anaemia Definition: Hb
More informationExtra Notes 3. Warm. In the core (center) of the body, where the temperature is 37 C.
Extra Notes 3 *The numbers of the slides are according to the last year slides. Slide 33 Autoimmune hemolytic anemia : Abnormal circulating antibodies that target normal antigen on the RBC and cause lysis.
More information6.1 Extended family screening
CHAPTER 6 CONCLUSION Cost benefit analysis of thalassemia screening programs have shown that the single years treatment for a β-thalassemia major patient was much higher than a total cost per case prevented.
More informationRBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
RBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Discuss the classification of anemia into hypochromic-microcytic, normochromicnormocytic and macrocytic. Categorize laboratory test procedures used in the
More informationScreening for haemoglobinopathies in pregnancy
Policy Statement All Southern Health patients will receive clinical care that reflects best practice and is based on the best available evidence. Index of chapters within background 1. Prevalence of haemoglobinopathies
More informationBONE MARROW PERIPHERAL BLOOD Erythrocyte
None Disclaimer Objectives Define anemia Classify anemia according to pathogenesis & clinical significance Understand Red cell indices Relate the red cell indices with type of anemia Interpret CBC to approach
More informationAnaemia in Pregnancy
Anaemia in Pregnancy Definition :anaemia is a pathological condition in which the oxygen-carrying capacity of red blood cells is insufficient to meet the body needs. The WHO : haemoglobin concentration
More informationHEMOLYTIC ANEMIA DUE TO ABNORMAL HEMOGLOBIN SYNTHESIS
Hemolytic Anemia Due to Abnormal Hemoglobin Synthesis MODULE 19 HEMOLYTIC ANEMIA DUE TO ABNORMAL HEMOGLOBIN SYNTHESIS 19.1 INTRODUCTION There are two main mechanisms by which anaemia is produced (a) Thalassemia:
More informationHAEMOGLOBINOPATHIES. Editing file. References: 436 girls & boys slides 435 teamwork slides. Color code: Important. Extra.
HAEMOGLOBINOPATHIES Objectives: normal structure and function of haemoglobin. how the globin components of haemoglobin change during development, and postnatally. the mechanisms by which the thalassaemias
More informationManagement of thalassaemia major
Archives of Disease in Childhood, 1983, 58, 1026-1030 Personal practice Management of thalassaemia major B MODELL AND M PETROU Department of Obstetrics and Gynaecology, University College Hospital, and
More informationDONE BY : RaSHA RAKAN & Bushra Saleem
DONE BY : RaSHA RAKAN & Bushra Saleem Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationDependance on chronic transfusion
Dependance on chronic transfusion Pr Saliou Diop Hematology Blood transfusion Dakar- Sénégal diop@cnts-dakar.sn Introduction Chronic transfusion: Regular use of blood transfusion in patients with chronic
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue
More informationRationale for RBC Transfusion in SCD
Rationale for RBC Transfusion in SCD Dilution of HgbS-containing RBCs via the addition of HgbA-containing cells from the blood of normal donors Suppression of erythropoietin release caused by the rise
More informationSusan Stegman, MD Medical Director AXA Equitable Life May 3, 2016
Susan Stegman, MD Medical Director AXA Equitable Life May 3, 2016 Underwriting impact Anemia overview Classification of anemia Specific anemia topics Iron deficiency anemia Thalassemia Megaloblastic anemia
More informationSurvival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital, Jeddah, KSA
JKAU: Med. Sci., Vol. 17 No. 1, pp: 19-28 (2010 A.D. / 1431 A.H.) DOI: 10.4197/Med. 17-1.3 Survival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital,
More informationSickle cell disease. Fareed Omar 10 March 2018
Sickle cell disease Fareed Omar 10 March 2018 Physiology Haemoglobin structure HbA2: 2α and 2δ chains (2-3%) HbF: 2α and 2γ chains (
More information4 Jumana Jihad Dr. Ahmad Mansour Dr. Ahmad Mansour
4 Jumana Jihad Dr. Ahmad Mansour Dr. Ahmad Mansour Anemia Decreased blood production Increased blood loss Hemolytic Hemorrhage Extravascular Intravascular Hemolytic (Further classification( Extrinsic Intrinsic
More informationSickle Cell Disease. Edward Malters, MD
Sickle Cell Disease Edward Malters, MD Introduction Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of Sickle Cell Disease (SCD) Inherited disorder due to homozygosity for the abnormal
More informationHemoglobinopathies Diagnosis and management
Hemoglobinopathies Diagnosis and management Morgan L. McLemore, M.D. Hematology/Leukemia Department of Hematology and Oncology Winship Cancer Institute at Emory University mlmclem@emory.edu Disclosures
More informationGUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
More informationGuideline developed by Shelley Crary, MD, MS,* in collaboration with the ANGELS team. Last reviewed by Shelley Crary, MD, MS, January 19, 2017.
Microcytic Anemia Guideline developed by Shelley Crary, MD, MS,* in collaboration with the ANGELS team. Last reviewed by Shelley Crary, MD, MS, January 19, 2017. Dr. Crary is a member of the hemophilia
More informationTransfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
More informationHeme Questions and Derivatives for the USMLE Step One Exam. Winter Storm Skylar Edition
Heme Questions and Derivatives for the USMLE Step One Exam Winter Storm Skylar Edition Howard J. Sachs, MD Howard@12DaysinMarch.com www.12daysinmarch.com Patient presents for routine preoperative evaluation
More informationNon-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital
Non-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital Introduction Transfusion dependency in thalassemia Transfusions seldom required
More informationCarrying Beta Thalassaemia A carrier can use this booklet to
Carrying Beta Thalassaemia A carrier can use this booklet to help explain carrying beta to their partner, blood relatives and others. show to any health professional (doctor, nurse or midwife) they see
More informationGeneral Characterisctics
Anemia General Characterisctics Definition: anemia is a decrease in red blood cells. Happens due to underproduction, increased destruction or loss of red cells. Diagnosis of anemia: Hgb < 135 (men) Hgb
More informationINTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED
INTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED Rationale for Combining Iron & Vit-D Vit D deficiency and Iron deficiency Anaemia the two most menacing disorders - are inter-related
More informationThalassemias:general aspects and molecular pathology
Thalassemias:general aspects and molecular pathology Prof. Renzo Galanello Pediatric Clinic 2 University of Cagliari Ospedale Regionale Microcitemie-ASL8 HEMOGLOBINOPATHIES CLASSIFICATION Structurally
More informationWiskott-Aldrich Syndrome
chapter 7 Wiskott-Aldrich Syndrome Wiskott-Aldrich syndrome is a primary immunodeficiency disease involving both T- and B-lymphocytes. In addition, the blood cells that help control bleeding, called platelets
More informationRisks and Benefits of Blood Transfusions. Objectives. Red Cells (Erythrocytes) Understand the following:
Risks and Benefits of Blood Transfusions Patient and Family Conference Aplastic Anemia & MDS International Foundation July 10-12 th, 2009 Indianapolis, Indiana Susan M. Carson RN, MSN, CPNP Childrens Hospital
More informationCOEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE?
COEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE? M. DE SLOOVERE (1), L. HARLET (2), S. VAN STEENWEGHEN (3), E. MOREAU (1), D. DE SMET (1) (1) DEPARTMENT OF LABORATORY MEDICINE,
More informationHEMOGLOBIN ELECTROPHORESIS DR ARASH ALGHASI SHAFA HOSPITAL-AHWAZ
HEMOGLOBIN ELECTROPHORESIS DR ARASH ALGHASI SHAFA HOSPITAL-AHWAZ Hemoglobin Hemoglobin (Hb), protein constituting 1/3 of the red blood cells Each red cell has 640 million molecules of Hb sites in the cells:
More informationA rare thing may be just like any other but it is also paradoxically nothing like any of them.
A rare thing may be just like any other but it is also paradoxically nothing like any of them. A RARE ANEMIA WHERE THERE IS PAUCITY AMIDST PLENTY. Dr.Rena, DNB Pediatrics Resident, Dr.Mehta s Children
More informationLa Terapia della Talassemia
S.I.E. Corso nazionale di aggiornamento in ematologia clinica La Terapia della Talassemia Renzo Galanello 15/06/2007 1 Clinica Pediatrica 2-Ospedale Regionale Microcitemie.ASL8 Clinical characteristics
More informationT HALASSEMIA S UPPORT F OUNDATION. The foundation provides hope, comfort and encouragement to those battling this disorder.
T HALASSEMIA S UPPORT F OUNDATION The foundation provides hope, comfort and encouragement to those battling this disorder. M ISSION STATEMENT The Thalassemia Support Foundation was founded by patients,
More informationRBCs Disorders 2. Dr. Nabila Hamdi MD, PhD
RBCs Disorders 2 Dr. Nabila Hamdi MD, PhD ILOs Discuss the classification of anemia into hypochromic-microcytic, normochromicnormocytic and macrocytic. Categorize laboratory test procedures used in the
More informationClinical Trial of Young Red Blood Cells Prepared by Apheresis
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 16, No. 6 Copyright 1986, Institute for Clinical Science, Inc. Clinical Trial of Young Red Blood Cells Prepared by Apheresis PATRICIA PISCIOTTO, M.D.,* THOMAS
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Alpha Thalassemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alpha_thalassemia 9/2013 7/2017 7/2018 7/2017 Description
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationEmergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: HEMATOLOGY Revised: 11/2013
Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: HEMATOLOGY Revised: 11/2013 What type of tissue is blood? Blood is considered liquid connective
More informationHematopoiesis, The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid.
Hematopoiesis, 200 billion new blood cells per day The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid. hematopoietic growth factors, proteins that regulate the proliferation
More informationThalassemia. By: Rebecca Chang (Period 6)
+ Thalassemia By: Rebecca Chang (Period 6) + Physiology Ø Two types of thalassemia: alpha and beta Ø Autosomal recessive inheritance pattern Ø Hemoglobin is damaged but symptoms greatly vary, especially
More informationCongenital Haemoglobinopathies
Congenital Haemoglobinopathies L. DEDEKEN, MD H O P I T A L U N I V E R S I T A I R E D E S E N F A N T S R E I N E F A B I O L A U N I V E R S I T E L I B R E DE B R U X E L L E S Red Blood Cell Disorders
More informationDr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan,
Dr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan, KSA amashi@moh.gov.sa 24/02/2018 β-thalassemia syndromes
More informationHemosiderin. Livia Vida 2018
Hemosiderin Livia Vida 2018 Questions Histochemical caracteristics of the different pigments. Exogenous pigments. Hemoglobinogenic pigments. Causes and forms of jaundice. Hemoglobinogenic pigments. Pathological
More informationMiss. kamlah ahmed 1
Miss. kamlah ahmed 1 Anatomy & Physiology Blood has two compartments: 1- a fluid portion called plasma. 2- a cellular portion known as the formed elements of the blood. Which are RBC (erythrocytes), WBC
More informationEducational Items Section
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Educational Items Section Hemoglobin genes; Sickle-cell anemia - Thalassemias Jean-Loup Huret, Xavier Troussard
More informationDr.Abdolreza Afrasiabi
Dr.Abdolreza Afrasiabi Thalassemia & Heamophilia Genetic Reaserch Center Shiraz Medical University Hemoglobin tetramer Hemoglobin Structure % A 1 α 2 β 2 94-97% A 2 α 2 δ 2 2.5% A 1C α 2 (β-n-glucose)
More information1. Adequate diet and iron intake to prevent iron deficiency 2. Signs and symptoms of malignant disease
Hematology/Oncology Description: The pediatric hematology-oncology division sees a wide spectrum of pediatric disease including but not limited to leukemia, hemophilia, solid tumors, ITP, and other blood
More informationSurvey of blood transfusion-induced malaria and other diseases in Thalassemia patients from Solapur District (M.S.) India.
7. CONCLUSION Over 125 patients affected by thalassemia live in Solapur District, Maharashtra, India. Thalassemia is a blood disease and is common in both sexes. Thalassemia was suspected in all these
More informationFig.No.1. Effect on RBCs
A Review on Thalassemia Debasis Das 1 *, Amartya De 1 1 BCDA College of Pharmacy and Technology,78, Jessore Road (south), Hridaypur, Barasat, Kolkata 700127. India. Corresponding Author: Debasis Das Email:
More informationIntroduction and II. Blood Cells A. Introduction
Chapter 14: Blood 1. Blood is three to four times more viscous than water. Introduction and II. Blood Cells A. Introduction 2. Most blood cells form in red bone marrow. 3. Types of blood cells are red
More informationBeta-thalassemia:clinical findings,molecular defects and genotype/phenotype relationships
Beta-thalassemia:clinical findings,molecular defects and genotype/phenotype relationships Maria Domenica Cappellini Fondazione Ca Granda Policlinico IRCCS University of Milan Disclosure Member of Advisory
More informationCPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB
CPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB Although relative resistance to the effect of ESAs is a common problem in managing the anemia of patients with CKD
More informationTransfusions in Sickle Cell Disease: How, When and Why
Transfusions in Sickle Cell Disease: How, When and Why James R. Eckman, MD Professor Emeritus of Hematology and Medical Oncology Emory University School of Medicine This work is supported by the Centers
More informationImpaired Antibody Response to Intravenous Immunization in Sickle Cell Anemia
Pediat. Res. 6: 15-19 (197) Heterophile antibody immunology sickle cell anemia spleen Impaired Antibody Response to Intravenous Immunization in Sickle Cell Anemia ALLEN D. SCHWARTZ 11 AND HOWARD A. PEARSON
More informationSickle Cell Disease and impact on the society
Sickle Cell Disease and impact on the society Professor Z.A.Jeremiah Ph.D, FRCPath (London) Professor of Haematology and Blood Transfusion Science Niger Delta University, Wilberforce Island Outline What
More informationReport of Beta Thalassemia in Newar Ethnicity
Report of Beta Thalassemia in Newar Ethnicity Rajendra Dev Bhatt 1*, Surendra Koju 2, Prabodh Risal 1 Affiliations: 1 Department of Clinical Biochemistry, Dhulikhel Hospital, Kathmandu University Hospital
More informationComprehensive Care for Children and Adolescents with Sickle Cell Diseases
Comprehensive Care for Children and Adolescents with Sickle Cell Diseases Objectives To review the system for newborn screening of infants for sickling diseases To provide the framework for a comprehensive
More informationBlood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?
What is blood transfusion? A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. A blood transfusion usually takes two to
More information